DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

South Korea · Delayed Price · Currency is KRW

3,705.00

+15.00 (0.41%)

At close: Aug 24, 2026

DongKoo Bio & Pharma Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	241,434	242,688	249,275	215,686	194,988	155,149
Revenue Growth	-0.46%	-2.64%	15.57%	10.62%	25.68%	11.45%
Gross Profit	139,730	144,342	151,887	132,076	117,860	92,337
Operating Income	339.04	9,248	12,691	14,616	16,836	8,139
Net Income	33,013	50,272	2,036	11,812	6,614	9,327
Earnings Per Share	1191.87	1791.00	75.00	427.63	238.29	330.05
EPS Growth	445.58%	2288.00%	-82.46%	79.46%	-27.80%	2.16%

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	51,011	35,165	36,250	22,898	35,136	32,100
Total Debt	122,630	128,782	86,641	43,804	34,322	24,294
Net Cash (Debt)	-71,619	-93,617	-50,391	-20,906	813.88	7,806
Net Cash Growth	-	-	-	-	-89.57%	33.61%
Net Cash Per Share	-2579.40	-3329.90	-1856.67	-756.89	29.32	276.23

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	21,195	-4,287	17,344	3,585	16,819	17,903
Capital Expenditures	-21,703	-17,656	-21,866	-13,845	-4,978	-4,266
Free Cash Flow	-507.99	-21,944	-4,522	-10,260	11,841	13,637
Free Cash Flow Growth	-	-	-	-	-13.16%	514.06%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	57.88%	59.48%	60.93%	61.23%	60.45%	59.51%
Operating Margin	0.14%	3.81%	5.09%	6.78%	8.63%	5.25%
Pretax Margin	17.78%	25.31%	1.53%	6.83%	4.06%	7.30%
Profit Margin	13.67%	20.71%	0.82%	5.48%	3.39%	6.01%
FCF Margin	-0.21%	-9.04%	-1.81%	-4.76%	6.07%	8.79%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 24, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	3.11	2.94	64.38	13.24	25.64	24.94
P/FCF Ratio	-	-	-	-	14.32	17.05
PS Ratio	0.41	0.61	0.53	0.73	0.87	1.50